Fresenius Medical Care (FMS) reported Q2 adjusted earnings Tuesday of 0.91 euro ($1.05) per share, up from 0.72 euro a year earlier.
Revenue for the quarter ended June 30 was 4.79 billion euros, compared with 4.77 billion euros a year earlier.
Analysts polled by FactSet expected 4.93 billion euros.
For fiscal 2025, the company reaffirmed its guidance for positive to low single-digit percent revenue growth year over year. Analysts surveyed by FactSet expect revenue of 19.55 billion euros.
Shares of the company were down more than 1% in recent Tuesday premarket activity.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。